Doctors can accurately gauge whether antiangiogenic treatments are working in melanoma patients by using CT imaging combined with measurements of a key biomarker. Medscape reports that researchers at the University of Mississippi Medical Center determined this in 46 melanoma patients treated with bevacizumab antiangiogenic therapy in a Phase II clinical trial. Through their technique, they learned that patients with higher levels of serum lactate dehydrogenase (LDH) had a worse chance of survival versus patients with low serum LDH. The research team was to present details of its work at the American Roentgen Ray Society 2013 Annual Meeting in Washington, D.C., according to the Medscape story. Story (sub. req.)